Skip to main content
. 2022 Aug 12;113(10):3510–3517. doi: 10.1111/cas.15496

FIGURE 1.

FIGURE 1

Candidate miRNA selection strategy in urothelial carcinoma. (A) Sample selection and inclusion in the training and validation sets. (B) Principal component analysis map of miRNA profiles from the 320 miRNAs in the training set. (C) Heat map showing differences in miRNA expression between patients with urothelial carcinoma and noncancer controls.